Clinical Trials Logo

Drug-eluting Balloon clinical trials

View clinical trials related to Drug-eluting Balloon.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05450042 Recruiting - Clinical trials for Peripheral Arterial Disease

Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation

Start date: April 6, 2022
Phase: N/A
Study type: Interventional

Endovascular treatment of symptomatic atherosclerotic peripheral artery disease (PAD) is recommended as the primary revascularization strategy. Percutaneous transluminal angioplasty (PTA) of the superficial femoral artery has a high initial success rate, but restenosis and dissections frequently occur.The influence of the novel devices with improved hemodynamic capabilities with respect to vasomotion of the vessel wall, vascular function and vascular compliance can be measured by FMD (flow-mediated dilation), arterial stiffness indices and vascular strain analysis. The aim of this ITT is to determine the potential improvement and impact of the SELUTION SLR in the infrainguinal arteries on local vascular function.

NCT ID: NCT04743180 Recruiting - Clinical trials for Peripheral Arterial Disease

European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

LUMIFOLLOW
Start date: January 18, 2021
Phase:
Study type: Observational [Patient Registry]

The objective of this all-comers registry is to explore the safety, efficacy, and cost-efficiency of the LUMINOR© DEB in de-novo and restenotic-FP lesions. For de-novo and restenotic lesions, especially for calcified and/or long lesions/occlusions, the use of debulking devices to improve recalibration and drug penetration will be evaluated in a specific sub-group.